Analyst Price Targets — CNTB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 14, 2026 12:43 pm | Edward Nash | Canaccord Genuity | $7.00 | $2.44 | TheFly | Connect Biopharma price target raised to $7 from $6 at Canaccord |
| July 9, 2026 11:57 am | — | Oppenheimer | $8.00 | $2.57 | TheFly | Connect Biopharma initiated with an Outperform at Oppenheimer |
| June 26, 2026 9:55 am | — | Piper Sandler | $7.00 | $2.07 | TheFly | Connect Biopharma initiated with an Overweight at Piper Sandler |
| June 18, 2026 10:49 am | Brandon Folkes | H.C. Wainwright | $7.00 | $2.08 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Connect Biopharma Holdings Ltd (CNTB) |
| May 26, 2026 9:23 am | Edward Nash | Canaccord Genuity | $6.00 | $2.35 | TheFly | Connect Biopharma initiated with a Buy at Canaccord |
| May 21, 2026 10:06 am | Olivia Brayer | Cantor Fitzgerald | $4.00 | $2.31 | TheFly | Connect Biopharma initiated with an Overweight at Cantor Fitzgerald |
| December 1, 2025 1:40 pm | Thomas Flaten | Lake Street | $9.00 | $2.86 | TheFly | Connect Biopharma initiated with a Buy at Lake Street |
| May 5, 2022 4:40 am | Joseph Catanzaro | Piper Sandler | $1.50 | $0.82 | TheFly | Connect Biopharma downgraded to Neutral from Overweight at Piper Sandler |
Latest News for CNTB
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C.
– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – Cash runway expected for a period of at least one year from the date of this release – SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the…
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12-month
CNTB is developing rademikibart, a drug with a similar mechanism of action to SNY/REGN's blockbuster Dupixent. The company is approaching a readout from two trials, Seabreeze STAT Asthma and Seabreeze STAT COPD, which have the potential to show a benefit of rademikibart for acute exacerbations. CNTB raised net proceeds of $18.6M in Q1'26 with a private placement, with cash of $46M at the end of that quarter.
– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway into 2H 2027 – SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CNTB.
U.S. House Trading
No House trades found for CNTB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.